Problem statement: why scrap quietly eats margins
High scrap rates on gamma-irradiation resistant trays can turn a profitable OEM run into a break-even slog. For buyers and supply managers from the Philippines up to Shenzhen, the immediate drivers are clear: material rejects after sterilization, fixture damage during handling, and inconsistent sterilization validation that forces whole lots to be held or destroyed. At recent shows like Medtec China and other medical industry trade shows, engineers and procurement leads kept circling back to the same problem — scrap, not specs, usually determines final cost. This piece maps the problem so you can act on it.
Root causes: where scrap really starts
Three recurring failures account for most loss: design-for-manufacture gaps, poor incoming inspection, and sterilization surprises. Design issues include tight wall thicknesses or unsupported ribs that craze under gamma irradiation. Incoming inspection failures are often missed micro-cracks or contamination—bioburden levels that only show after irradiation. Sterilization surprises come from inconsistent dose mapping or an SAL mismatch; when dose distribution isn’t uniform, certain trays fail integrity checks and entire batches get scrapped.
Practical fixes at the sourcing stage
Start by tightening design requirements in your RFQ. Insist on DFM rules for irradiation—blended radii, minimum wall thicknesses, and robust tray fixtures that protect product cavities. Include acceptance criteria for bioburden (for example, a 14-day bioburden incubation limit for batch release tests) and require suppliers to describe their sterilization validation approach. Set a pass/fail list for incoming inspection items: dimensional tolerance, surface finish, and visible stress marks. When you write contracts, build in sample retention terms (commonly 36 months for validated lots) so you can trace failures without ambiguity.
Process controls suppliers must prove
Demand clear documentation on gamma irradiation processes: dose mapping, dose audits, and sterility assurance level (SAL) demonstration. Require suppliers to reference ISO 11137 and to provide its relevant sub-chapter intent:- ISO 11137‑1: Requirements for development, validation and routine control of a sterilization process for medical devices- ISO 11137‑2: Establishing the sterilization dose- ISO 11137‑3: Guidance on dosimetric aspectsThese show they understand both process and dosimetry. Also look for suppliers using calibrated dosimeters and a documented process for handling pack density changes between runs.
Inspection, validation and trial runs
Validation is non-negotiable. Run a pilot with full-pass production specimens, and insist on documented sterilization validation and retention samples. Use physical stress testing (drop, stack, thermal cycling) prior to irradiation; these usually reveal fixture or material weaknesses long before any lot reaches the sterilizer. Keep records of lot-level dosimetry and correlate with post-irradiation inspection to close the loop on failure causes.
Supplier partnerships, audits and total cost view
Choosing the cheapest mould house often backfires. Audits should include process flows, clean-room rules, lot traceability, and a review of failure mode effects. Track scrap both as a percentage of production and as absolute cost per part — those two metrics tell different stories. Pursue shared KPIs with your supplier: first-pass yield, ppm rework, and time-to-root-cause. When suppliers invest in tooling changes that reduce scrap, a modest cost share will pay back fast.
Common mistakes to avoid
Avoid three common pitfalls: (1) accepting prototypes as production quality, (2) skipping dose-mapping for different pack configurations, and (3) treating sterilization as a checkbox rather than a process variable. Also, don’t neglect simple things like how trays are palletised—mechanical damage in transit is a frequent, avoidable scrap source. — These small misses add up.
Golden rules for evaluation (Advisory)
1) Inspect with purpose: evaluate suppliers on first-pass yield, not just defect counts. 2) Validate comprehensively: require ISO 11137‑based dose mapping and retain samples for the agreed period (commonly 36 months). 3) Share responsibility: structure contracts so tooling fixes and DFM changes are co-funded when they reduce long-term scrap.
Careful sourcing and clear technical demands cut scrap and stabilise cost — and for teams attending regional events, the market insight you gather from shows matters. Medtec. — Trust practice over promises.
